Michael S Poslusney

US Patent:

20130123236, May 16, 2013

Filed:

Nov 10, 2012

Appl. No.:

13/674016

Inventors:

VANDERBILT UNIVERSITY - Nashville TN, US
P. Jeffrey Conn - Brentwood TN, US
Michael R. Wood - Brentwood TN, US
Corey R. Hopkins - Nolensville TN, US
Bruce J. Melancon - Nashville TN, US
Michael S. Poslusney - Nashville TN, US

Assignee:

VANDERBILT UNIVERSITY - Nashville TN

International Classification:

C07D 487/10
C07D 491/113
C07D 491/107
C07D 471/10

US Classification:

51421021, 5483575, 514406, 544331, 514275, 546 17, 514278, 546 15

Abstract:

In one aspect, the invention relates to substituted benzylspiroindolin-2-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M(mAChR M); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20130289207, Oct 31, 2013

Filed:

Dec 12, 2011

Appl. No.:

13/993698

Inventors:

Rubina G. Parmar - Harleysville PA, US
Michael Steven Poslusney - Nashville TN, US
Weimin Wang - Churchville PA, US
J. Michael Williams - Hillsborough NJ, US

International Classification:

A61K 47/48

US Classification:

525 542, 528340

Abstract:

The present invention provides membrane lytic poly(amido amine) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.

US Patent:

20130084346, Apr 4, 2013

Filed:

Feb 28, 2011

Appl. No.:

13/582601

Inventors:

Scott Wolkenberg - Wyndmoor PA, US
James C. Barrow - Arnold MD, US
Michael S. Poslusney - Nashville TN, US
Scott T. Harrison - Glenside PA, US
B. Wesley Trotter - Medfield MA, US
James Mulhearn - Elkins Park PA, US
Kausik K. Nanda - Norristown PA, US
Peter J. Manley - Harleysville PA, US
Zhijian Zhao - Wilmington DE, US
Jeffrey W. Schubert - Ambler PA, US
Nathan Kett - Columbia TN, US
Amy Zartman - Hatfield PA, US

International Classification:

C07D 213/69
C07D 401/10
A61K 31/4439
C07D 213/73
C07D 213/74
C07F 5/02
A61K 31/69
A61K 31/444
C07D 401/14
C07D 471/04
A61K 31/4725
A61K 31/4709
A61K 45/06
C07D 413/10
A61K 31/5377
A61K 31/4545
C07D 417/10
A61K 31/541
C07D 413/12
A61K 31/4418

US Classification:

424722, 546296, 514348, 5462734, 514338, 546 13, 514 64, 546258, 514334, 546256, 514333, 546113, 514300, 546261, 514335, 546144, 514307, 546173, 514314, 514221, 544131, 5142355, 5462754, 514341, 5462774, 514339, 546194, 514318, 544 582, 5142278, 5462757

Abstract:

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

US Patent:

20220251090, Aug 11, 2022

Filed:

Feb 1, 2022

Appl. No.:

17/590404

Inventors:

- Baltimore MD, US
James C. Barrow - Arnold MD, US
Ingrid Buchler - Baltimore MD, US
Michael Poslusney - Baltimore MD, US

International Classification:

C07D 487/04
A61P 1/12

Abstract:

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.

US Patent:

20210139479, May 13, 2021

Filed:

Jan 22, 2021

Appl. No.:

17/155371

Inventors:

- Baltimore MD, US
Glen Ernst - Bear DE, US
Dominique Swinnen - Braine I'Alleud, BE
Florian Montel - Meitingen, DE
Sabine Defays - Tubize, BE
Yifeng Huang - Lansdale PA, US
Pablo de Leon - Baltimore MD, US
Michael Steven Poslusney - Owings Mills MD, US

International Classification:

C07D 471/04
A61P 25/00
A61K 31/165
A61K 31/197
A61K 31/4985

Abstract:

This invention relates to compounds, pharmaceutical compositions and their use for treating neuropsychiatric and neurodegenerative disorders. In particular, the invention relates to inhibitors of catechol-O-methyltransferase and their use as therapeutics for central nervous system disease.

US Patent:

20200231592, Jul 23, 2020

Filed:

Mar 18, 2020

Appl. No.:

16/823130

Inventors:

- Nashville TN, US
P. Jeffrey Conn - Nashville TN, US
Michael R. Wood - Westwood MA, US
Corey R. Hopkins - Nolensville TN, US
Bruce J. Melancon - South Bend IN, US
Michael S. Poslusney - Owings Mills MD, US
Darren W. Engers - Brentwood TN, US

International Classification:

C07D 471/04
C07D 401/14
C07D 401/10
C07D 403/10
C07D 405/10
C07D 417/10
C07D 275/06
C07D 519/00
C07D 487/04

Abstract:

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M(mAChR M); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

US Patent:

20180305354, Oct 25, 2018

Filed:

Nov 25, 2016

Appl. No.:

15/779340

Inventors:

- Baltimore MD, US
Glen Ernst - Bear DE, US
Dominique Swinnen - Braine l'Alleud, BE
Florian Montel - Meitingen, DE
Sabine Defays - Tubize, BE
Yifang Huang - Lansdale PA, US
Pablo de LEÓN - Baltimore MD, US
Michael Steven Poslusney - Owings Mills MD, US

International Classification:

C07D 471/04
A61K 31/4985
A61K 31/197
A61K 31/165

Abstract:

Compounds that inhibit COMT enzyme and pharmaceutical compositions comprising the same are provided herein. Methods of treating various psychiatric and neurological disorders with the compounds and pharmaceutical compositions described herein are also provided.

US Patent:

20180179205, Jun 28, 2018

Filed:

Feb 22, 2018

Appl. No.:

15/902547

Inventors:

- Nashville TN, US
P. Jeffrey Conn - Nashville TN, US
Michael R. Wood - Westwood MA, US
Corey R. Hopkins - Nolensville TN, US
Bruce J. Melancon - South Bend IN, US
Michael S. Poslusney - Owings Mills MD, US
Darren W. Engers - Brentwood TN, US

International Classification:

C07D 471/04
C07D 487/04
C07D 519/00
C07D 275/06
C07D 417/10
C07D 403/10
C07D 401/10
C07D 401/14
C07D 405/10

Abstract:

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M(mAChR M); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.